Stock 1530 3SBIO INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials 3SBio Inc.

Equities

1530

KYG8875G1029

Pharmaceuticals

Delayed Hong Kong S.E.
Other stock markets
 22:19:35 2024-05-02 EDT 		5-day change 1st Jan Change
6.55 HKD -0.46% Intraday chart for 3SBio Inc. +13.79% -13.30%
04-22 3Sbio Inc. Announces Management Changes CI
04-15 3SBIO Gets China Nod for Use of Cancer Injection in Children with Thrombocytopenia MT

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Capitalization 1 22,384 22,926 15,136 13,359 17,878 14,516 14,516 -
Enterprise Value (EV) 1 23,886 23,645 14,959 13,120 20,196 18,543 15,346 13,517
P/E ratio 18 x 23.8 x 18 x 8.54 x 9.91 x 11 x 8 x 7.28 x
Yield - - - 3.78% 1.24% 2.64% 3.58% 4.17%
Capitalization / Revenue 4.88 x 4.31 x 2.71 x 2.09 x 2.61 x 2.1 x 1.68 x 1.53 x
EV / Revenue 5.21 x 4.45 x 2.68 x 2.06 x 2.94 x 2.37 x 1.77 x 1.43 x
EV / EBITDA 13.4 x 11.8 x 9.31 x 5.99 x 7.22 x 6.7 x 5.39 x 4.38 x
EV / FCF 26.5 x 16.9 x 33.1 x 23.9 x 15.9 x 11.2 x 11.2 x 7.11 x
FCF Yield 3.78% 5.93% 3.02% 4.19% 6.29% 8.96% 8.97% 14.1%
Price to Book 2.6 x 2.38 x 1.41 x 1.1 x 1.36 x 1.01 x 0.95 x 0.86 x
Nbr of stocks (in thousands) 2,538,985 2,539,974 2,543,601 2,522,355 2,438,845 2,382,112 2,382,112 -
Reference price 2 8.816 9.026 5.950 5.296 7.330 6.094 6.094 6.094
Announcement Date 19-03-20 20-03-30 21-03-30 22-03-28 23-03-21 24-03-20 - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Net sales 1 4,584 5,318 5,588 6,382 6,859 7,816 8,661 9,458
EBITDA 1 1,782 2,005 1,606 2,190 2,796 2,768 2,846 3,088
EBIT 1 1,212 1,652 1,503 1,642 1,658 1,915 2,503 2,723
Operating Margin 26.45% 31.06% 26.89% 25.73% 24.18% 24.51% 28.9% 28.79%
Earnings before Tax (EBT) 1 1,496 1,223 979.1 1,869 2,274 1,978 2,377 2,613
Net income 1 1,277 973.7 835.8 1,651 1,915 1,549 1,937 2,137
Net margin 27.86% 18.31% 14.96% 25.87% 27.92% 19.82% 22.37% 22.59%
EPS 2 0.4900 0.3800 0.3300 0.6200 0.7400 0.6200 0.7618 0.8376
Free Cash Flow 1 902.9 1,403 451.6 549.2 1,271 1,372 1,376 1,901
FCF margin 19.7% 26.38% 8.08% 8.61% 18.53% 17.61% 15.89% 20.1%
FCF Conversion (EBITDA) 50.68% 69.96% 28.12% 25.08% 45.44% 50.46% 48.35% 61.57%
FCF Conversion (Net income) 70.7% 144.06% 54.03% 33.26% 66.36% 67.22% 71.01% 88.99%
Dividend per Share 2 - - - 0.2000 0.0912 0.1608 0.2180 0.2540
Announcement Date 19-03-20 20-03-30 21-03-30 22-03-28 23-03-21 24-03-20 - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2019 S1 2019 S2 2020 S1 2020 S2 2021 S1 2021 S2 2022 S1 2022 S2 2023 S1 2023 S2 2024 S1 2024 S2 2025 S1 2025 S2
Net sales 1 2,643 2,675 2,695 2,892 3,110 3,275 3,091 3,768 3,784 4,032 4,352 4,631 4,498 5,254
EBITDA - - - - - - - - - - - - - -
EBIT 1 - - - - 915.3 727 802.5 855.8 1,301 614.8 1,427 1,312 1,496 1,494
Operating Margin - - - - 29.43% 22.2% 25.96% 22.71% 34.38% 15.25% 32.8% 28.32% 33.25% 28.43%
Earnings before Tax (EBT) - - - - - - - - - - - - - -
Net income - - - - - - - - - - - - - -
Net margin - - - - - - - - - - - - - -
EPS 2 0.1300 0.2500 0.2700 0.0600 0.3400 0.2800 0.3700 0.3700 0.3900 0.2300 0.4400 0.3900 0.4500 0.4400
Dividend per Share - - - - - - - - - - - - - -
Announcement Date 19-08-21 20-03-30 20-08-17 21-03-30 21-08-25 22-03-28 22-08-24 23-03-21 23-08-24 24-03-20 - - - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Net Debt 1 1,502 719 - - 2,318 2,148 830 -
Net Cash position 1 - - 177 239 - - - 999
Leverage (Debt/EBITDA) 0.843 x 0.3587 x - - 0.8291 x 0.776 x 0.2918 x -
Free Cash Flow 1 903 1,403 452 549 1,271 1,372 1,376 1,901
ROE (net income / shareholders' equity) 16% 10.7% 8.23% 15.1% 15.2% 11.5% 12.5% 12.4%
ROA (Net income/ Total Assets) 9.26% 6.8% 5.15% 8.95% 9.3% 6.79% 8.23% 8.38%
Assets 1 13,796 14,324 16,244 18,445 20,601 22,817 23,531 25,509
Book Value Per Share 2 3.390 3.800 4.220 4.810 5.400 6.040 6.400 7.110
Cash Flow per Share 2 0.4200 0.7400 0.4900 0.5700 0.8200 0.8400 0.7700 1.170
Capex 1 247 471 893 1,029 910 820 905 842
Capex / Sales 5.4% 8.86% 15.98% 16.13% 13.26% 10.52% 10.45% 8.9%
Announcement Date 19-03-20 20-03-30 21-03-30 22-03-28 23-03-21 24-03-20 - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for 3SBio Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
6.094 CNY
Average target price
6.893 CNY
Spread / Average Target
+13.12%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
3SBIO INC. Stock 3SBio Inc.
-13.30% 1.91B
CSL LIMITED Stock CSL Limited
-3.45% 86.16B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+2.76% 40.17B
BIOGEN INC. Stock Biogen Inc.
-17.49% 31.47B
UCB Stock UCB
+54.44% 25.24B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-13.13% 15.82B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-9.12% 11.96B
INCYTE CORPORATION Stock Incyte Corporation
-15.45% 11.89B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-42.56% 11.61B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+4.87% 8.84B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. 1530 Stock
  4. Financials 3SBio Inc.